Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Zarina Yelskaya

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Plos One|June 1, 2013
Synergistic inhibition of survival, proliferation, and migration of U87 cells with a combination of LY341495 and IressaZarina Yelskaya, Vangie Carrillo, Ewa Dubisz, et al.
European Journal of Human Genetics : EJHG|February 23, 2021
Resolving pathogenicity classification for the CDH1 c.[715G>A] (p.Gly239Arg) VariantZarina Yelskaya, Angela G Arnold, Vanessa J Marcell, et al.
European Journal of Human Genetics : EJHG|April 28, 2021
Correction to: Resolving pathogenicity classification for the CDH1 c.[715G>A] (p.Gly239Arg) variantZarina Yelskaya, Angela G Arnold, Vanessa J Marcell, et al.
NPJ Precision Oncology|June 8, 2026
Independent somatic TP53 mutations in blood and tumor mimicking Li-Fraumeni syndrome in a 94-year-old manChuan Gao, Vikas Rai, Donna Wong, et al.
Plos One|November 24, 2016
CDH1 Missense Variant c.1679C>G (p.T560R) Completely Disrupts Normal Splicing through Creation of a Novel 5' Splice SiteZarina Yelskaya, Ruben Bacares, Erin Salo-Mullen, et al.
Plos One|February 24, 2017
Osteosarcoma cell proliferation and survival requires mGluR5 receptor activity and is blocked by RiluzoleSally Liao, Yuleisy Ruiz, Hira Gulzar, et al.
JAMA Oncology|June 7, 2018
Prevalence of Clonal Hematopoiesis Mutations in Tumor-Only Clinical Genomic Profiling of Solid TumorsRyan N Ptashkin, Diana L Mandelker, Catherine C Coombs, et al.
BMC Medical Genomics|May 21, 2017
Comprehensive detection of germline variants by MSK-IMPACT, a clinical diagnostic platform for solid tumor molecular oncology and concurrent cancer predisposition testingDonavan T Cheng, Meera Prasad, Yvonne Chekaluk, et al.
NPJ Precision Oncology|January 2, 2023
Expanded genetic testing of GIST patients identifies high proportion of non-syndromic patients with germline alterationsDiana Mandelker, Antonio Marra, Nikita Mehta, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 22, 2023
Genomic Profiling Reveals Germline Predisposition and Homologous Recombination Deficiency in Pancreatic Acinar Cell CarcinomaDiana Mandelker, Antonio Marra, Binbin Zheng-Lin, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Plos One|June 1, 2013
Synergistic inhibition of survival, proliferation, and migration of U87 cells with a combination of LY341495 and IressaZarina Yelskaya, Vangie Carrillo, Ewa Dubisz, et al.
European Journal of Human Genetics : EJHG|February 23, 2021
Resolving pathogenicity classification for the CDH1 c.[715G>A] (p.Gly239Arg) VariantZarina Yelskaya, Angela G Arnold, Vanessa J Marcell, et al.
European Journal of Human Genetics : EJHG|April 28, 2021
Correction to: Resolving pathogenicity classification for the CDH1 c.[715G>A] (p.Gly239Arg) variantZarina Yelskaya, Angela G Arnold, Vanessa J Marcell, et al.
NPJ Precision Oncology|June 8, 2026
Independent somatic TP53 mutations in blood and tumor mimicking Li-Fraumeni syndrome in a 94-year-old manChuan Gao, Vikas Rai, Donna Wong, et al.
Plos One|November 24, 2016
CDH1 Missense Variant c.1679C>G (p.T560R) Completely Disrupts Normal Splicing through Creation of a Novel 5' Splice SiteZarina Yelskaya, Ruben Bacares, Erin Salo-Mullen, et al.
Plos One|February 24, 2017
Osteosarcoma cell proliferation and survival requires mGluR5 receptor activity and is blocked by RiluzoleSally Liao, Yuleisy Ruiz, Hira Gulzar, et al.
JAMA Oncology|June 7, 2018
Prevalence of Clonal Hematopoiesis Mutations in Tumor-Only Clinical Genomic Profiling of Solid TumorsRyan N Ptashkin, Diana L Mandelker, Catherine C Coombs, et al.
BMC Medical Genomics|May 21, 2017
Comprehensive detection of germline variants by MSK-IMPACT, a clinical diagnostic platform for solid tumor molecular oncology and concurrent cancer predisposition testingDonavan T Cheng, Meera Prasad, Yvonne Chekaluk, et al.
NPJ Precision Oncology|January 2, 2023
Expanded genetic testing of GIST patients identifies high proportion of non-syndromic patients with germline alterationsDiana Mandelker, Antonio Marra, Nikita Mehta, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 22, 2023
Genomic Profiling Reveals Germline Predisposition and Homologous Recombination Deficiency in Pancreatic Acinar Cell CarcinomaDiana Mandelker, Antonio Marra, Binbin Zheng-Lin, et al.
Pageof 2